<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178070</url>
  </required_header>
  <id_info>
    <org_study_id>GENOR GB224-001; V1.4</org_study_id>
    <nct_id>NCT04178070</nct_id>
  </id_info>
  <brief_title>Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalated Phase Ⅰ Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Gerilimzumab in Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genor Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genor Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the safety, tolerability and&#xD;
      pharmacokinetic (PK) profiles of single-dose, dose-escalated, abdominal subcutaneous&#xD;
      injection of GB224 in Chinese healthy adult subjects. The secondary objectives are to&#xD;
      preliminarily understand the immunogenicity and pharmacodynamic variable (IL-6) of single&#xD;
      abdominal subcutaneous injection of GB224 in Chinese healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adeverse Effect, AE</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Adeverse Effect, AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adeverse Effect, AE</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Serious Adeverse Effect, AE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose, MTD</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Maximum Tolerated Dose, MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Limited Toxicity, DLT</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Dose Limited Toxicity, DLT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>AUC0-t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Vd</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ke</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Ke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Retention Time, MRT</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>Mean Retention Time, MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>t1/2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL</measure>
    <time_frame>Up to 112 days.</time_frame>
    <description>CL</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>GB224 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB224 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 5mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 10mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 15mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 20mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 30mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 2mg</intervention_name>
    <description>2mg (100μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 2mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 5mg</intervention_name>
    <description>5mg (250μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 5mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 10mg</intervention_name>
    <description>10mg (500μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 10mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 15mg</intervention_name>
    <description>15mg (750μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 15mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 20mg</intervention_name>
    <description>20mg (1mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 20mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GB224 30mg</intervention_name>
    <description>30mg (1.5mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 30mg</arm_group_label>
    <other_name>Gerilimzumab injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 2mg</intervention_name>
    <description>2mg (100μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 5mg</intervention_name>
    <description>5mg (250μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 10mg</intervention_name>
    <description>10mg (500μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 15mg</intervention_name>
    <description>15mg (750μL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 20mg</intervention_name>
    <description>20mg (1mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>Placebo 20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo, 30mg</intervention_name>
    <description>30mg (1.5mL), single dose, abdominal subcutaneous injection</description>
    <arm_group_label>GB224 30mg</arm_group_label>
    <arm_group_label>Placebo 30mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Understand the study procedures and contents, and voluntarily sign the informed&#xD;
             consent form;&#xD;
&#xD;
          2. Chinese healthy adult volunteers aged 18 to 45 years, males and females;&#xD;
&#xD;
          3. The subjects have qualified physical examination within 30 days before the study, the&#xD;
             body mass index (BMI) is within the range of 19~24 and the body weight is within the&#xD;
             range of 45~75kg;&#xD;
&#xD;
          4. Males or females agree to adopt medically confirmed effective contraceptive measures&#xD;
             during the entire study period and within 6 months after the end of this study.&#xD;
&#xD;
          5. The investigator considers that the patients have good health condition according to&#xD;
             the physical examination, medical history, vital signs and ECG etc.&#xD;
&#xD;
          6. Patients have good compliance, can receive follow-up visits as scheduled, are able to&#xD;
             well communicate with the investigators and complete the study as required by the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any of the following is met: allergic constitution; known allergic to the components&#xD;
             of the investigational product or allergy history to any drug or food or pollen;&#xD;
             subjects who have medical history of skin allergy such as physical urticaria; subjects&#xD;
             who have abnormal serum immunoglobulin E (IgE) test;&#xD;
&#xD;
          2. Any of the current symptoms, signs or laboratory test abnormalities indicating the&#xD;
             possible presence of acute or subacute infection (e.g., pyrexia, cough, urgent&#xD;
             micturition, urodynia, abdominal pain, diarrhea, cutaneous infected wound etc.)&#xD;
&#xD;
          3. Patients with active pulmonary tuberculosis; patients who previously had medical&#xD;
             history of active pulmonary tuberculosis;&#xD;
&#xD;
          4. Subjects who have medical history of drug addiction or drug abuse;&#xD;
&#xD;
          5. Subjects who have clear medical history of central nervous system, cardiovascular,&#xD;
             renal, hepatic, gastrointestinal, respiratory, metabolic system or subjects with other&#xD;
             significant diseases; subjects with medical history of hypertension or screening&#xD;
             systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg, which are&#xD;
             clinically significant at the discretion of the investigators; subjects who have&#xD;
             medical history of orthostatic hypotension;&#xD;
&#xD;
          6. Subjects who have medical history of malignant tumors;&#xD;
&#xD;
          7. Subjects who participated in other clinical studies within 3 months before enrollment,&#xD;
             or subjects who received drugs which are known to injure the major organs within 3&#xD;
             months before enrollment;&#xD;
&#xD;
          8. Subjects who used prescription drugs or non-prescription drugs within 14 days before&#xD;
             enrollment;&#xD;
&#xD;
          9. Subjects who have blood donation history within 3 months before enrollment;&#xD;
&#xD;
         10. Subjects who meet any of the following criteria: alanine aminotransferase (ALT) or&#xD;
             aspartate aminotransferase (AST) &gt;1.5 times the upper limit of normal (ULN), serum&#xD;
             creatinine (Cr) &gt; the upper limit of normal (ULN);&#xD;
&#xD;
         11. Abnormal routine blood tests: any of the following is met: white blood cells&#xD;
             (WBC)&lt;3.0×109/L or &gt;9.5×109/L, neutrophil count (ANC)&lt;1.5×109/L, platelet count&#xD;
             (PLT)&lt;100×109/L, hemoglobin (HGB)&lt;104g/L;&#xD;
&#xD;
         12. Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C&#xD;
             antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and&#xD;
             anti-treponema pallidum antibody (TP-Ab);&#xD;
&#xD;
         13. Subjects who have positive tuberculosis skin test (5 units of dosage, induration of&#xD;
             not less than 5 millimeters (mm) within 48 ~ 72 hours);&#xD;
&#xD;
         14. Subjects with positive anti-nuclear antibody (ANA), anti-double stranded DNA antibody&#xD;
             (ds-DNA) and anti-extractable nuclear antigens (ENA);&#xD;
&#xD;
         15. Subjects with positive anti-drug antibody (ADA);&#xD;
&#xD;
         16. Subjects with positive tumor markers (CEA, AFP, PSA and CA-125);&#xD;
&#xD;
         17. Subjects with abnormal coagulation function, which is clinically significant at the&#xD;
             discretion of the investigators;&#xD;
&#xD;
         18. Subjects with medical history of psychiatric disorders;&#xD;
&#xD;
         19. Smoking more than 5 cigarettes/day or equivalent tobacco;&#xD;
&#xD;
         20. Weekly alcohol consumption more than 28 units (1 unit = 285 mL of beer or 25 mL of&#xD;
             spirits or a glass of wine); or subjects who have positive breath alcohol test within&#xD;
             24 hours before the use of investigational drug;&#xD;
&#xD;
         21. Subjects who have clinically significant abnormal laboratory test values at screening;&#xD;
&#xD;
         22. Female subjects who have positive serum/urine pregnancy tests at screening or&#xD;
             lactating women;&#xD;
&#xD;
         23. Patients who have insufficient communication, understanding and cooperation; or&#xD;
             patients who have poor compliance and cannot guarantee to strictly follow the study&#xD;
             protocol;&#xD;
&#xD;
         24. Subjects who are considered unsuitable for participating in this study for various&#xD;
             reasons at the discretion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Fang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn Yu, Master</last_name>
    <phone>010-65260820</phone>
    <email>Shawn.Yu@genorbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Fang, Ph.D</last_name>
      <phone>010-66583834</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

